Synlogic company info

What does Synlogic do?
Synlogic (NASDAQ:SYBX) is pioneering the development and commercialization of a promising and innovative field known as synthetic biotics. Harnessing the power of genetically engineered microbes, Synlogic's projects aim to tackle a range of challenges in the medical and health sectors. Their work includes groundbreaking approaches to treat metabolic disorders, infections, and other diseases by manipulating the functions of living cells to perform therapeutic tasks. Their objective is centered on transforming the lives of patients by advancing the science of synthetic biology to produce living medicines that act in a precise, controlled fashion to treat disease at its source. Synlogic's dedication to innovation reflects their commitment to addressing unmet medical needs through the novel realm of synthetic biotics.
Synlogic company media
Company Snapshot

Is Synlogic a public or private company?

key
Ownership
Public

How many people does Synlogic employ?

people
Employees
6

What sector is Synlogic in?

pie chart
Sector
Health Care

Where is the head office for Synlogic?

location pin
Head Office
Massachusetts, United States

What year was Synlogic founded?

founded flag
Year Founded
2014
What does Synlogic specialise in?
/Synthetic Biotic /Pharmaceutical Research /Therapeutic Development /Metabolic Diseases /Cancer Therapies /Clinical Trials

What are the products and/or services of Synlogic?

Overview of Synlogic offerings
Lrabafenogene marselecobac (SYNB1934): This is their most advanced product candidate, currently being studied in a global Phase 3 trial (Synpheny-3) as a potential treatment for phenylketonuria (PKU). PKU is a rare inherited metabolic disorder that affects the body's ability to process the amino acid phenylalanine.
SYNB6248: This is a product candidate in Phase 1/2a clinical trial for the treatment of homocystinuria (HCU), another rare inherited metabolic disorder.
SYNB8802: This is a product candidate in preclinical development for the treatment of enteric hyperoxaluria, a condition that causes excessive oxalate production in the gut.
Synlogic also has programs targeting gout and cystinuria, both of which are rare metabolic disorders.

Who is in the executive team of Synlogic?

Synlogic leadership team
  • Mr. Antoine  Awad
    Mr. Antoine Awad
    Principal Executive Officer & COO
  • Dr. Timothy K. Lu M.D., Ph.D.
    Dr. Timothy K. Lu M.D., Ph.D.
    Co-Founder & Member of Scientific Advisory Board
  • Dr. James J. Collins Ph.D.
    Dr. James J. Collins Ph.D.
    Co-Founder & Member of Scientific Advisory Board
  • Ms. Mary Beth Dooley
    Ms. Mary Beth Dooley
    Head of Finance and Principal Financial Officer & Principal Accounting Officer
  • Mr. Brendan St. Amant
    Mr. Brendan St. Amant
    General Counsel & Corporate Secretary
  • Mr. Ajay  Munshi
    Mr. Ajay Munshi
    Vice President of Corporate Development
  • Mr. Adam J. Thomas
    Mr. Adam J. Thomas
    Chief People Officer
  • Dr. Caroline B. Kurtz Ph.D.
    Dr. Caroline B. Kurtz Ph.D.
    Chief Development Officer